Literature DB >> 26296145

GANGLION CELL LAYER THICKNESS AND VISUAL IMPROVEMENT AFTER EPIRETINAL MEMBRANE SURGERY.

Su Jeong Song1, Mi Yeon Lee, William E Smiddy.   

Abstract

PURPOSE: To evaluate the possible prognostic value of preoperative individual retinal layer thicknesses measured by an automated algorithm from spectral domain optical coherence tomography and visual acuity or improvement after epiretinal membrane surgery.
METHODS: Data from 76 eyes with idiopathic epiretinal membrane that underwent pars plana vitrectomy for idiopathic epiretinal membrane removal were analyzed. The preoperative thicknesses of the ganglion cell layer, inner plexiform layer, and other layers were measured using the Iowa Reference Algorithm. Each retinal layer thickness and its ratio of the central foveal thickness were compared between eyes with (Group 1) or without (Group 2) 2 or more Snellen lines of visual improvement at 3, 6, and 12 months after surgery.
RESULTS: Higher mean central foveal thickness/ganglion cell layer ratio and symptom duration of ≤1 year were significantly more common in Group 1 (P = 0.03 and 0.04, respectively). After adjusting for age and symptom duration, lens status, and preoperative visual acuity, higher central foveal thickness/ganglion cell layer ratio was associated with ≥2 lines of visual improvement after surgery (odds ratio: 6.57, 95% confidence interval: 1.29-33.40).
CONCLUSION: The preoperative inner retinal layer changes may have a role independent of outer retinal layer parameters in the visual prognosis after epiretinal membrane peeling.

Entities:  

Mesh:

Year:  2016        PMID: 26296145     DOI: 10.1097/IAE.0000000000000705

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

1.  Evaluation of postoperative visual function based on the preoperative inner layer structure in the epiretinal membrane.

Authors:  Hiroko Terashima; Fumiki Okamoto; Hiruma Hasebe; Naoki Matsuoka; Eriko Ueda; Hiromitsu Yoshida; Tetsuya Togano; Takeo Fukuchi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-06-07       Impact factor: 3.117

2.  Elevated M2 Macrophage Markers in Epiretinal Membranes With Ectopic Inner Foveal Layers.

Authors:  Jiwon Baek; Hye Yeon Park; Jae Hoon Lee; Mihyun Choi; Ji Hyun Lee; Minji Ha; Mee Yon Lee
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-02-07       Impact factor: 4.799

3.  Changes in Metamorphopsia, Visual Acuity, and Central Macular Thickness after Epiretinal Membrane Surgery in Four Preoperative Stages Classified with OCT B-Scan Images.

Authors:  Jianbo Mao; Hanfei Wu; Chenyi Liu; Chenting Zhu; Jimeng Lao; Yiqi Chen; Jiwei Tao; Yun Zhang; Lijun Shen
Journal:  J Ophthalmol       Date:  2019-06-17       Impact factor: 1.909

4.  Efficacy and Safety of Combined Vitrectomy with Intravitreal Dexamethasone Implant for Advanced Stage Epiretinal Membrane.

Authors:  Claudio Iovino; Giuseppe Giannaccare; Marco Pellegrini; Federico Bernabei; Mirco Braghiroli; Tomaso Caporossi; Enrico Peiretti
Journal:  Drug Des Devel Ther       Date:  2019-12-03       Impact factor: 4.162

5.  Association between individual retinal layer thickness and visual acuity in patients with epiretinal membrane: a pilot study.

Authors:  Jing Zou; Wei Tan; Wenlong Huang; Kangcheng Liu; Fangling Li; Huizhuo Xu
Journal:  PeerJ       Date:  2020-07-10       Impact factor: 2.984

6.  Anatomical and Functional Recovery Kinetics After Epiretinal Membrane Removal.

Authors:  Filippos Vingopoulos; Ismini Koulouri; John B Miller; Demetrios G Vavvas
Journal:  Clin Ophthalmol       Date:  2021-01-15

7.  Tight adherent feature on optical coherence tomography predict postoperative visual outcome in epiretinal membrane eyes.

Authors:  Tzu-Ting Lai; Li-Li Wu; Yi-Ting Hsieh; Chia-Chen Lee; Yi-Jie Peng
Journal:  BMC Ophthalmol       Date:  2022-08-18       Impact factor: 2.086

8.  Long-Term Outcomes After Idiopathic Epiretinal Membrane Surgery.

Authors:  Abdelrahman M Elhusseiny; Harry W Flynn; William E Smiddy
Journal:  Clin Ophthalmol       Date:  2020-03-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.